Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range

BACKGROUND Renal denervation (RDN) has been shown to lower blood pressure (BP), but its effects on cardiovascular events have only been preliminarily evaluated. Time in therapeutic range (TTR) of BP is associated with cardiovascular events.OBJECTIVES This study sought to assess the impact of catheter-based RDN on TTR and its association with cardiovascular outcomes in the GSR (Global SYMPLICITY Registry).METHODS Patients with uncontrolled hypertension were enrolled and treated with radiofrequency RDN. Office and ambulatory systolic blood pressure (OSBP and ASBP) were measured at 3, 6, 12, 24, and 36 months postprocedure and used to derive TTR. TTR through 6 months was assessed as a predictor of cardiovascular events from 6 to 36 months using a Cox proportional hazard regression model.RESULTS As of March 1, 2022, 3,077 patients were enrolled: 42.2% were female; mean age was 60.5 +/- 12.2 years; baseline OSBP was 165.6 +/- 24.8 mm Hg; and baseline ASBP was 154.3 +/- 18.7 mm Hg. Patients were prescribed 4.9 +/- 1.7 antihypertensive medications at baseline and 4.8 +/- 1.9 at 36 months. At 36 months, mean changes were -16.7 +/- 28.4 and -9.0 +/- 20.2 mm Hg for OSBP and ASBP, respectively. TTR through 6 months was 30.6%. A 10% increase in TTR after RDN through 6 months was associated with significant risk reductions from 6 to 36 months of 15% for major adverse cardiovascular events (P < 0.001), 11% cardiovascular death (P = 0.010), 15% myocardial infarction (P = 0.023), and 23% stroke (P < 0.001).CONCLUSIONS There were sustained BP reductions and higher TTR through 36 months after RDN. A 10% increase in TTR through 6 months was associated with significant risk reductions in major cardiovascular events from 6 to 36 months. (Global SYMPLICITY Registry [GSR] DEFINE; NCT01534299) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.